Business context and reporting period
The filing is Organovo Holdings, Inc.’s Form 10-K for the fiscal year ended March 31, 2022—not a quarterly report. The company name in the request metadata, “Vivosim Labs, INC.,” does not match the registrant identified in the filing. Organovo is an early-stage biotechnology company developing 3D human tissue models to study disease and identify drug targets, initially focused on ulcerative colitis and Crohn’s disease. It reported no meaningful revenue from ongoing operations and described its business strategy as early-stage and unproven.
Financial results and liquidity
| Metric | FY ended March 31, 2022 | FY ended March 31, 2021 |
|---|---|---|
| Revenue | $1.5 million | None |
| Research and development expense | $3.3 million | $1.1 million |
| Selling, general and administrative expense | $9.7 million | $15.7 million |
| Operating loss | $11.5 million | $16.8 million |
| Net loss | $11.4 million | $16.8 million |
| Cash used in operating activities | $8.5 million | $13.3 million |
| Cash and cash equivalents at year-end | $28.7 million | $37.4 million |
FY2022 revenue was a one-time $1.5 million upfront payment for a non-exclusive patent license to BICO Group AB; Organovo reported no sales-based royalty revenue for the year. Gross margin is not separately reported. Working capital was $28.1 million, compared with $37.7 million a year earlier. Total liabilities were $3.1 million, including $2.2 million of operating lease liabilities; the filing does not report conventional borrowings.
Material changes versus the prior year
- Research and development expense increased 201% as the company expanded activity after its 2020 change in control; average full-time R&D headcount rose from two to nine.
- SG&A expense declined 39%, primarily because the prior year included executive departures, severance and accelerated stock compensation. FY2022 also included substantial patent-related legal costs, which management said should not recur following settlement.
- Operating cash use decreased by $4.8 million, while cash declined by $8.7 million overall. FY2021 financing had provided $23.8 million; FY2022 financing provided $0.2 million.
- Cash and cash equivalents fell by $8.7 million year over year. Accumulated deficit reached $307.7 million.
Outlook, risks and unusual items
- Management expects FY2023 operating expenses of $10 million to $12 million and believes current cash will fund operations for at least 12 months under its current plan. It also says additional capital will be needed to execute its business plan; funding availability and terms are uncertain.
- Key risks include recurring losses, the unproven tissue-model and drug-discovery strategy, dependence on reliable human-cell supplies, need for financing and strategic partners, and uncertain development and regulatory timelines. COVID-19 could disrupt research, supply chains and fundraising.
- On February 22, 2022, Organovo settled patent disputes with BICO Group AB, granted a non-exclusive license and received the $1.5 million upfront payment. The related litigation and patent-review proceedings were dismissed. Ongoing sales-based royalties may be payable, but none were recognized for FY2022 because the company lacked complete sales information and considered the variable consideration constrained.
- The company reports related-party services and shared facilities and equipment with Viscient Biosciences, whose leadership and personnel overlap with Organovo. It identifies potential conflicts of interest.
- The financial statements received an unqualified audit opinion. The auditor reported no critical audit matters and did not audit internal control effectiveness; management concluded its controls were effective as of March 31, 2022.
Most important facts for investors to verify
- Confirm the intended issuer and period: this is Organovo Holdings’ annual report for the year ended March 31, 2022.
- Review cash burn, the 12-month runway assumption and the company’s financing plans, including potential dilution from its shelf and at-the-market offerings.
- Check progress on intestinal disease models, target validation, partnerships and any transition toward drug candidates; the filing reports no drug candidates identified under the new strategy.
- Review the BICO license’s ongoing royalty terms and the company’s future royalty reporting, as well as continuing obligations under university licenses.
- Assess related-party arrangements and potential conflicts involving Viscient Biosciences.